GlassScriptPhysician profile
Patrick S Walsh
NPI 1508279266
$1,250.12
in general payments reported to CMS, 2019-2025
12 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $139 · 2021: $190 · 2022: $205 · 2023: $157 · 2024: $230 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $208.22 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $165.69 | 2019-2021 | |
| Abbvie INC. | $156.13 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Johnson & Johnson Vision Care, INC. | $153.84 | 2019-2024 | Acuvue |
| Bausch & Lomb Americas INC. | $143.36 | 2023-2025 | Vyzulta |
| Tarsus Pharmaceuticals, INC. | $119.43 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $89.27 | 2019-2025 | Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $45.20 | 2020-2022 | |
| Shire North American Group INC | $38.44 | 2019 | |
| Sun Pharmaceutical Industries INC. | $34.17 | 2021 | |
| Kala Pharmaceuticals, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.